H G Hass
Overview
Explore the profile of H G Hass including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hass H, Muthny F, Stepien J, Lerch J, von der Marwitz C, Schrock R, et al.
Rehabilitation (Stuttg)
. 2017 Jun;
56(3):189-197.
PMID: 28599338
Benefit and long-term effects of rehabilitation and psychoeducational interventions after cancer therapy are still controversial discussed. Aim of the study was to evaluate feasibility and effects of a telephone-based follow-up...
2.
von Einem J, Heinemann V, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass H, et al.
J Cancer Res Clin Oncol
. 2014 May;
140(9):1607-14.
PMID: 24816724
Purpose: AIO KRK-0104 investigated first-line therapy of metastatic colorectal cancer (mCRC) with cetuximab, capecitabine and irinotecan versus cetuximab, capecitabine and oxaliplatin. This analysis investigated the impact of primary tumor location...
3.
Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass H, Dietzfelbinger H, et al.
Br J Cancer
. 2011 Jul;
105(2):206-11.
PMID: 21750558
Background: The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine...
4.
Hass H, Denzlinger C
Z Gastroenterol
. 2009 Jan;
47(1):27-9.
PMID: 19156589
Aim: Hepatocellular carcinoma (HCC) is the 5th most common human malignancy with an increasing incidence in western countries and still unsatisfactory median survival rates of 5 - 7 months. Currently,...
5.
Nehls O, Oettle H, Hartmann J, Hofheinz R, Hass H, Horger M, et al.
Br J Cancer
. 2008 Jan;
98(2):309-15.
PMID: 18182984
This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination therapy (CAPOX) in advanced biliary system adenocarcinomas. Patients received oxaliplatin (130 mg m(-2),...
6.
Nehls O, Okech T, Hsieh C, Enzinger T, Sarbia M, Borchard F, et al.
Br J Cancer
. 2007 Apr;
96(9):1409-18.
PMID: 17426704
We evaluated the expression patterns of proapoptotic BAX, antiapoptotic Bcl-2 and p53, the proposed upstream effector of these molecules, as potential prognostic markers in UICC stage III colon cancer by...
7.
Nehls O, Hass H, Weber P, Dette S, Lauer U, Schlemmer H, et al.
Endoscopy
. 2007 Mar;
38 Suppl 2:E65-6.
PMID: 17366421
No abstract available.
8.
Hass H, Kaiser S
Dtsch Med Wochenschr
. 2006 Oct;
131(40):2213-6.
PMID: 17021989
Case History: A 56-year-old woman presented with increased liver enzymes (GPT, GOT), arthralgias, Raynaud's syndrome and disturbance of sleep and concentration. Findings And Diagnosis: Serology and liver biopsy indicated chronic...
9.
Hass H, Nagele T, Seeger U, Hosl F, Gregor M, Kaiser S
Z Gastroenterol
. 2005 Apr;
43(4):373-8.
PMID: 15830303
Hepatic encephalopathy (HE) is a common problem in liver cirrhosis and is associated with typical changes of cerebral metabolite pattern observed by proton magnetic resonance spectroscopy (MRS). In HE, a...
10.
Hass H, Nehls O, Gregor M, Kaiser S, Kreysel C
Dig Liver Dis
. 2004 Jun;
36(5):367-8.
PMID: 15191208
No abstract available.